OTC : CLVLY

Clinuvel Pharmaceuticals Limited

$6.95 USD

$0 (0.0%)

Volume
21.66K
Average Volume
3K
Market Capitalization
$350.47M
P/E Ratio
15.48
Dividend Yield
0.50%
Price Target
Year High
$9.00
Year Low
$5.98
Day High
—
Day Low
—
Payout Ratio
$0.08
Current Ratio
$14.64
Company Overview

OTC

Philippe Jacques Wolgen

Biotechnology

Healthcare

CLVLY

100

AU

USD

https://www.clinuvel.com

61 3 9660 4900

188769103

0001290877

Liquidity Metrics

0.00

14.64

14.17

2.02

0.08

Sales & Valuation

$95.02M

5.27

2.03

12.65

0.80

Profitability

$0.72

$36.17M

33.79%

45.90%

13.29%

12.07%

P/E Metrics

15.48

-0.99

-0.99

Analyst Price Target & Rating

Buy

4/5

0 Analysts

%

Financial Health Scores

17.85

5/9

$243.29M

$269.43M

$20.66M

$91.32M

Key Metrics (TTM)

$471.34M

4.89

11.32

14.64

13.29%

11.07%

6.45%

7.90%

$8.51

39 days

Company Executives
Name Title
Malcolm Bull Head of Australian Operations & Investor Relations
Philippe Jacques Wolgen Chief Executive Officer, MD & Director
Azza Hamila Head of Quality Assurance & Drug Safety
Peter Vaughan Chief Financial Officer
Claire Newstead-Sinclair Company Secretary
Dennis J. Wright Chief Scientific Officer
Emilie Rodenburger Director of Global Clinical Affairs
Linda Teng Director of North American Operations
Lachlan Hay Chief Operations Officer
Poll Results

No votes yet today — be the first to share your view!

About Clinuvel Pharmaceuticals Limited (OTC:CLVLY) Stock

Clinuvel Pharmaceuticals Limited is a biopharmaceutical firm dedicated to creating and marketing therapies for individuals worldwide grappling with genetic, metabolic, and severe medical conditions, operating across Australia, Europe, the United States, and Switzerland. Their flagship therapeutic, SCENESSE, is a systemic photoprotective medication designed to shield adult patients suffering from erythropoietic protoporphyria (EPP) from light-induced damage. The company's development portfolio also features CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which stimulates extended cellular activity; and PRÉNUMBRA, an injectable liquid form of afamelanotide. Clinuvel Pharmaceuticals has forged a partnership with HK Winhealth Pharma Group Co. Limited to d ... eliver SCENESSE to EPP patients in the People's Republic of China through a specialized named patient program. Established in 1987, the company maintains its principal office in Melbourne, Australia.

CLINUVEL implements strategic reorganisation to refocus on U.S. markets

2026-07-23 00:10:00

MELBOURNE, Australia and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD (ASX: CUV | Nasdaq: CUVL) today announced a strategic reorganisation of its operations and workforce, effective 1 January 2027, concurrent with the relocation of its corporate headquarters to the United States.

CLINUVEL's ADS to commence trading on Nasdaq

2026-07-20 01:37:00

MELBOURNE, Australia and NEW YORK, July 20, 2026 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD today announced that its American Depositary Share (ADS) is expected to commence trading on the Nasdaq Stock Market (Nasdaq) later today (New York time) under the ticker symbol CUVL. The announcement follows the declaration from the U.S. Securities and Exchange Commission (SEC) on 17 July that the Company's publicly filed 20-F Registration Statement is deemed effective, and approval received from Nasdaq to list the ADS.

SCENESSE® approved for EPP in Canada

2026-07-13 01:10:00

Health Canada NOC enables treatment for porphyria, metabolic disorder Health Canada NOC enables treatment for porphyria, metabolic disorder

Frequently Asked Questions

What is the current Clinuvel Pharmaceuticals Limited (CLVLY) stock price?

Clinuvel Pharmaceuticals Limited(OTC:CLVLY) stock price is $6.95 in the last trading session. During the trading session, CLVLY stock reached the peak price of $9 while $5.98 was the lowest point it dropped to. The percentage change in CLVLY stock occurred in the recent session was 0.0% while the dollar amount for the price change in CLVLY stock was $0.

CLVLY's industry and sector of operation?

The OTC listed CLVLY is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of CLVLY?

Malcolm Bull | Head of Australian Operations & Investor Relations
Philippe Jacques Wolgen | Chief Executive Officer, MD & Director
Azza Hamila | Head of Quality Assurance & Drug Safety
Peter Vaughan | Chief Financial Officer
Claire Newstead-Sinclair | Company Secretary

How many employees does CLVLY have?

Number of CLVLY employees currently stands at 100. CLVLY operates from 535 Bourke Street, Melbourne, VIC 3000, AU.

Link for CLVLY official website?

Official Website of CLVLY is: https://www.clinuvel.com

How do I contact CLVLY?

CLVLY could be contacted at phone #61 3 9660 4900 and can also be accessed through its website. CLVLY operates from 535 Bourke Street, Melbourne, VIC 3000, AU.

How many shares of CLVLY are traded daily?

The average number of CLVLY shares traded daily for last 3 months was 3K.

What is the market cap of CLVLY currently?

The market value of CLVLY currently stands at $350.47M with its latest stock price at $6.95